The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.50
Bid: 29.00
Ask: 30.00
Change: -0.50 (-1.67%)
Spread: 1.00 (3.448%)
Open: 29.50
High: 29.50
Low: 29.50
Prev. Close: 30.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Placing and Retail Offer

9 Jul 2021 16:07

RNS Number : 8191E
Ilika plc
09 July 2021
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS NOT AN OFFER FOR SALE OR SUBSCRIPTION IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER OF OR SOLICITATION TO PURCHASE OR SUBSCRIBE FOR SECURITIES IN THE UNITED STATES.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

For immediate release

9 July 2021

Ilika plc

 

Result of Placing and Retail Offer

 

Ilika plc (AIM: IKA), the advanced solid-state battery company ("Ilika", the "Company" or, together with its subsidiary undertakings, the "Group"), is pleased to announce that, following the announcement made earlier today (the "Launch Announcement") regarding the launch of a proposed placing (the "Placing"), it has successfully placed 12,846,428 new ordinary shares of one penny each ("Ordinary Shares") (the "Placing Shares") at a price of 140 pence per share (the "Issue Price") raising gross proceeds of approximately £18.0 million.

 

The Company is also pleased to announce that, following the further announcement made earlier today regarding the launch of a proposed retail offering via PrimaryBid (the "Retail Offer"), it has successfully placed 2,142,857 new Ordinary Shares (the "Retail Shares") at the Issue Price, raising gross proceeds of approximately £3.0 million.

 

Certain of the directors of the Company (the "Directors" or the "Board") have also directly conditionally subscribed with the Company for, in aggregate, 10,713 new Ordinary Shares at the Issue Price (the "Director Subscription Shares").

 

Liberum Capital Limited ("Liberum") is acting as nominated adviser and joint bookrunner in connection with the Placing. Joh. Berenberg, Gossler & Co. KG ("Berenberg" and together with Liberum, the "Joint Bookrunners") is acting as joint bookrunner in connection with the Placing.

 

Capitalised terms not defined in this announcement (this "Announcement") have the meanings given to them in the Launch Announcement.

 

The Issue Price represents a discount of approximately 30.0 per cent. to the closing mid-market price of 200 pence per Ordinary Share on 8 July 2021, being the last business day prior to the Launch Announcement.

The EIS/VCT Placing is conditional, inter alia, upon:

(i) the Placing Agreement becoming unconditional in all respects (save for any condition relating to EIS/VCT Admission) and not having been terminated in accordance with its terms prior to EIS/VCT Admission;

 

(ii) the passing of the Resolutions at the General Meeting (or any adjournment thereof); and

 

(iii) EIS/VCT Admission becoming effective by no later than 8.00 a.m. on or around 29 July 2021 (or such later time and/or date (being no later than 8.00 a.m. on the Long Stop Date) as the Joint Bookrunners and the Company may agree).

 

Application will be made for the EIS/VCT Placing Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on 29 July 2021.

 

The General Placing is conditional, inter alia, upon:

(i) EIS/VCT Admission having occurred;

 

(ii) the Placing Agreement becoming unconditional in all respects (save for any condition relating to General Admission) and not having been terminated in accordance with its terms prior to General Admission; and

 

(iii) General Admission becoming effective by no later than 8.00 a.m. on or around 30 July 2021 (or such later time and/or date (being no later than 8.00 a.m. on the Long Stop Date) as the Joint Bookrunners and the Company may agree).

 

Application will be made for the General Placing Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on 30 July 2021.

 

As announced earlier today, Ilika also intends to raise up to approximately £3.7 million through the issue of up to 2,673,811 new Ordinary Shares (the "Open Offer Shares") pursuant to an open offer (the "Open Offer"), to allow Ilika shareholders, including those who are not participating in the Placing or the Retail Offer, to subscribe for new Ordinary Shares at the Issue Price. The Company intends to publish and send a circular to shareholders in connection with the Open Offer (the "Circular") on or around 12 July 2021. The Circular will also be available on the Company's website: www.ilika.com.

 

Related Party Transactions

GPIM Limited and Henderson Global Investors (the "Substantial Shareholders") are considered to be related parties of the Company for the purposes of Rule 13 of the AIM Rules for Companies by virtue of their status as substantial shareholders of the Company.

 

The Substantial Shareholders have agreed to subscribe for 331,146 and 1,285,714 Placing Shares, respectively, as part of the Placing.

 

The Directors, having consulted with the Company's nominated adviser, Liberum, consider that the terms of the terms of the Placing are fair and reasonable insofar as the shareholders of the Company are concerned.

 

Director Subscriptions

The following Directors have conditionally subscribed for New Ordinary Shares in the following amounts and pursuant to the Director Subscription Agreements:

 Director

Existing beneficial shareholding

New Ordinary Shares subscribed for

Shareholding on completion of the Placing

Shareholding as a percentage of the Enlarged Issued Share Capital*

Keith Jackson

95,000

7,142

102,142

0.1

Monika Biddulph

12,500

3,571

16,071

0.0

* assuming all of the Open Offer Shares are taken up under the terms of the Open Offer

In addition, Steve Boydell, Brian Hayden and Graeme Purdy intend to exercise options entitling them to 10,000, 8,000 and 30,000 new Ordinary Shares respectively in accordance with the terms of the Company's bonus scheme as soon as reasonably practicable following the General Meeting, conditionally on the Capital Raising becoming unconditional.

 

For more information contact:

 

Ilika plc

 

 

 

www.ilika.com

Graeme Purdy, Chief Executive

Via Walbrook PR

Steve Boydell, Finance Director

 

 

 

Liberum Capital Limited

Tel: 020 3100 2000

Andrew Godber Cameron Duncan, William Hall, Nikhil Varghese

 

 

 

Joh. Berenberg, Gossler & Co. KG

Tel: 020 3207 7800

Emily Morris, Detlir Elezi, Alamgir Ahmed, Milo Bonser

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / Ilika@walbrookpr.com

Tom Cooper

Mob: 0797 122 1972

Lianne Cawthorne

Mob: 07584 391 303

Nick Rome

Mob: 07748 325 236

 

 

Note:

The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU Regulation No. 596/2014) (as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018) (the "UK MAR"). Upon the publication of this Announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. If you have any queries on this, then please contact Steve Boydell, Finance Director of the Company (the person responsible for arranging the release of this Announcement) on 0203 8011 1400.

 

IMPORTANT NOTICES

This Announcement includes statements that are, or may be deemed to be, "forward-looking statements". These forward- looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "forecasts", "plans", "prepares", "anticipates", "projects", "expects", "intends", "may", "will", "seeks", "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Announcement and include statements regarding the Company's and the Directors' intentions, beliefs or current expectations concerning, amongst other things, the Company's prospects, growth and strategy. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. The Company's actual performance, achievements and financial condition may differ materially from those expressed or implied by the forward-looking statements in this Announcement. In addition, even if the Company's results of operations, performance, achievements and financial condition are consistent with the forward-looking statements in this Announcement, those results or developments may not be indicative of results or developments in subsequent periods. Any forward-looking statements that the Company makes in this Announcement speak only as of the date of such statement and (other than in accordance with their legal or regulatory obligations) neither the Company, nor the Joint Bookrunners nor any of their respective associates, directors, officers or advisers undertakes any obligation to update such statements. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

Liberum is authorised and regulated by the Financial Conduct Authority (the "FCA") in the United Kingdom and is acting exclusively for the Company and no one else in connection with the Placing or any other matters referred to in this Announcement, and Liberum will not be responsible to anyone (including any Placees) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this Announcement.

Berenberg, which is authorised and regulated by the German Federal Financial Supervisory Authority and in the United Kingdom is deemed authorised under the Temporary Permissions Regime and subject to limited regulation by the FCA, is acting exclusively for the Company in connection with the Placing and will not be acting for any other person (including any Placees) and will not be responsible to any person other than the Company for providing the protections afforded to clients of Berenberg or for advising any other person in respect of the matters referred to in this Announcement.

No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Joint Bookrunners or by any of its affiliates or agents as to, or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.

No statement in this Announcement is intended to be a profit forecast or estimate, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.

The New Ordinary Shares to be issued pursuant to the Capital Raising will not be admitted to trading on any stock exchange other than the AIM market of the London Stock Exchange.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROISSLFIUEFSESW
Date   Source Headline
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.